Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bronchial Neoplasms

ClinicalTrials.gov lists 7,921 trials for Bronchial Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 205.

MeSH D001984 Neoplasms Neoplasm C04 C08
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,448 Phase 1/2 Phase 1/2 832 Phase 2 Phase 2 2,671 Phase 2/3 Phase 2/3 91 Phase 3 Phase 3 836 Phase 4 Phase 4 100 Not applicable Not applicable 712 Observational Observational 1,188 Phase 1 Phase 1 1,448 Phase 1/2 Phase 1/2 832 Phase 2 Phase 2 2,671 Phase 2/3 Phase 2/3 91 Phase 3 Phase 3 836 Phase 4 Phase 4 100 Not applicable Not applicable 712 Observational Observational 1,188

Trials per phase (log scale)

2 more sections with rows

55 of the 7,921 trials are tagged with Bronchial Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Bronchial Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bronchial Neoplasms trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 527

1990: 1 trials (Not applicable 1) 1991: 2 trials (Phase 2 1, Phase 1 1) 1992: 1 trials (Phase 2 1) 1993: 4 trials (Phase 2 2, Phase 1 2) 1994: 7 trials (Phase 3 5, Phase 2 1, Phase 1 1) 1995: 13 trials (Not applicable 1, Phase 3 4, Phase 2 3, Phase 1/2 1, Phase 1 4) 1996: 15 trials (Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 3) 1997: 21 trials (Observational 1, Phase 3 4, Phase 2 8, Phase 1/2 4, Phase 1 4) 1998: 46 trials (Observational 4, Not applicable 2, Phase 3 13, Phase 2 18, Phase 1/2 3, Phase 1 6) 1999: 51 trials (Observational 1, Not applicable 3, Phase 3 11, Phase 2 20, Phase 1/2 3, Phase 1 13) 2000: 81 trials (Observational 7, Not applicable 2, Phase 3 16, Phase 2/3 1, Phase 2 32, Phase 1/2 5, Phase 1 18) 2001: 66 trials (Observational 3, Not applicable 2, Phase 3 14, Phase 2/3 3, Phase 2 28, Phase 1/2 4, Phase 1 12) 2002: 100 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 21, Phase 2/3 2, Phase 2 51, Phase 1/2 4, Phase 1 13) 2003: 121 trials (Observational 9, Not applicable 4, Phase 3 11, Phase 2 65, Phase 1/2 14, Phase 1 18) 2004: 153 trials (Observational 9, Not applicable 12, Phase 4 2, Phase 3 17, Phase 2 74, Phase 1/2 13, Phase 1 26) 2005: 170 trials (Observational 16, Not applicable 8, Phase 3 19, Phase 2/3 3, Phase 2 88, Phase 1/2 10, Phase 1 26) 2006: 225 trials (Observational 17, Not applicable 15, Phase 4 2, Phase 3 32, Phase 2/3 1, Phase 2 120, Phase 1/2 16, Phase 1 22) 2007: 221 trials (Other 1, Observational 17, Not applicable 8, Phase 4 4, Phase 3 30, Phase 2/3 4, Phase 2 95, Phase 1/2 18, Phase 1 44) 2008: 249 trials (Observational 30, Not applicable 16, Phase 4 7, Phase 3 27, Phase 2/3 1, Phase 2 106, Phase 1/2 24, Phase 1 38) 2009: 250 trials (Observational 27, Not applicable 24, Phase 4 5, Phase 3 27, Phase 2/3 3, Phase 2 99, Phase 1/2 14, Phase 1 51) 2010: 198 trials (Observational 38, Not applicable 19, Phase 4 2, Phase 3 16, Phase 2/3 1, Phase 2 58, Phase 1/2 22, Phase 1 42) 2011: 189 trials (Observational 19, Not applicable 21, Phase 4 4, Phase 3 26, Phase 2/3 5, Phase 2 66, Phase 1/2 13, Phase 1 35) 2012: 202 trials (Other 1, Observational 36, Not applicable 26, Phase 4 2, Phase 3 16, Phase 2/3 1, Phase 2 73, Phase 1/2 17, Phase 1 30) 2013: 213 trials (Observational 27, Not applicable 23, Phase 4 3, Phase 3 20, Phase 2/3 4, Phase 2 77, Phase 1/2 15, Phase 1 44) 2014: 214 trials (Observational 32, Not applicable 26, Phase 4 5, Phase 3 22, Phase 2/3 4, Phase 2 61, Phase 1/2 20, Phase 1 44) 2015: 281 trials (Observational 42, Not applicable 18, Phase 4 3, Phase 3 30, Phase 2/3 7, Phase 2 81, Phase 1/2 38, Phase 1 62) 2016: 341 trials (Observational 65, Not applicable 31, Phase 4 2, Phase 3 36, Phase 2/3 2, Phase 2 84, Phase 1/2 43, Phase 1 78) 2017: 360 trials (Observational 70, Not applicable 26, Phase 4 7, Phase 3 28, Phase 2/3 5, Phase 2 103, Phase 1/2 51, Phase 1 70) 2018: 394 trials (Observational 65, Not applicable 50, Phase 4 5, Phase 3 40, Phase 2/3 2, Phase 2 113, Phase 1/2 42, Phase 1 77) 2019: 372 trials (Observational 66, Not applicable 34, Phase 4 11, Phase 3 30, Phase 2/3 3, Phase 2 108, Phase 1/2 40, Phase 1 80) 2020: 410 trials (Observational 86, Not applicable 24, Phase 4 4, Phase 3 42, Phase 2/3 4, Phase 2 130, Phase 1/2 44, Phase 1 76) 2021: 490 trials (Observational 85, Not applicable 51, Phase 4 5, Phase 3 45, Phase 2/3 3, Phase 2 154, Phase 1/2 62, Phase 1 85) 2022: 449 trials (Observational 78, Not applicable 44, Phase 4 4, Phase 3 31, Phase 2/3 5, Phase 2 139, Phase 1/2 62, Phase 1 86) 2023: 415 trials (Observational 84, Not applicable 41, Phase 4 2, Phase 3 37, Phase 2/3 3, Phase 2 116, Phase 1/2 56, Phase 1 76) 2024: 504 trials (Observational 91, Not applicable 52, Phase 4 8, Phase 3 56, Phase 2/3 3, Phase 2 148, Phase 1/2 48, Phase 1 98) 2025: 527 trials (Observational 100, Not applicable 54, Phase 4 2, Phase 3 58, Phase 2/3 11, Phase 2 157, Phase 1/2 53, Phase 1 92)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 473
2025 527
2024 504
2023 415
2022 449
2021 490
2020 410
2019 372
2018 394
2017 360

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 550 trials starting in 2026 and about 540 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 1,184 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 4,268 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bronchial Neoplasms trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,448
Phase 1/2 832
Phase 2 2,671
Phase 2/3 91
Phase 3 836
Phase 4 100
Not applicable 712
Observational 1,188
Expanded access 42
Unknown 1

How many Bronchial Neoplasms trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 411
Recruiting 1,239
Enrolling by invitation 33
Active, not recruiting 622
Available 10

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bronchial Neoplasms trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 205
AstraZeneca 196
Eli Lilly and Company 151
Pfizer 128
Hoffmann-La Roche 101

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Bronchial Neoplasms? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 422
(nab)-paclitaxel 421
NIVOLUMAB 213
DURVALUMAB 184
Osimertinib 162

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
or carboplatin 720
Cisplatin 1 454
Pemetrexe 418
Docetetaxel 359
Gemcitabine/Gemzar 257

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bronchial Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 8,615 676
Malignant neoplasm progression 5,282 139
Dyspnoea 4,235 517
Febrile neutropenia 3,004 396
Anaemia 2,661 425

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bronchial Neoplasms? (43)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Frontiers in endocrinology 2021 Yes
Diagnostic Outcomes and Safety of Cryobiopsy Added to Conventional Sampling Methods: An Observational Study. Chest 2021 Yes
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016 Yes
Bronchoscopic Cryotherapy. Clinical Applications of the Cryoprobe, Cryospray, and Cryoadhesion. Annals of the American Thoracic Society 2016 Yes
Endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes. Japanese journal of clinical oncology 2014 Yes

Showing 5 of 43 publications.

Start your 14-day trial Email me all 43 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages